{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:55:24Z","timestamp":1793058924139,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1074, B6"],"award-info":[{"award-number":["SFB1074, B6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB1074, B6"],"award-info":[{"award-number":["SFB1074, B6"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1038\/s41375-025-02591-w","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T12:34:21Z","timestamp":1744720461000},"page":"1520-1525","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+\u2009B-cell acute lymphoblastic leukemia by venetoclax"],"prefix":"10.1038","volume":"39","author":[{"given":"Alexandra","family":"Niedermayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Stursberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke Katharina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Cario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-3001","authenticated-orcid":false,"given":"Felix","family":"Seyfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3059-7544","authenticated-orcid":false,"given":"L\u00fcder Hinrich","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-1886","authenticated-orcid":false,"given":"Klaus-Michael","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2591_CR1","unstructured":"M Schrappe (2018, July -); Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017, ClinicalTrials.gov ID NCT03643276."},{"key":"2591_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMoa1110169","volume":"366","author":"M Schrappe","year":"2012","unstructured":"Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, et al. Outcomes after induction failure in childhood acute lymphoblastic leukemia. N Engl J Med. 2012;366:1371\u201381.","journal-title":"N Engl J Med"},{"key":"2591_CR3","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW, et al. Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov. 2021;11:1440\u201353.","journal-title":"Cancer Discov"},{"key":"2591_CR4","doi-asserted-by":"crossref","unstructured":"Groupe Fran\u00e7ais de Cytog\u00e9n\u00e9tique H\u00e9matologique (GFCH). t(10;11)(p13\u201314;q14\u201321): A New Recurrent Translocation in T-Cell Acute Lymphoblastic Leukemias. Genes Chromosom Cancer. 1991;3:411\u20135.","DOI":"10.1002\/gcc.2870030602"},{"key":"2591_CR5","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.leukres.2012.07.008","volume":"36","author":"C Borel","year":"2012","unstructured":"Borel C, Dastugue N, Cances-Lauwers V, Mozziconacci MJ, Prebet T, Vey N, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res. 2012;36:1365\u20139.","journal-title":"Leuk Res"},{"key":"2591_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/jha2.922","volume":"5","author":"H Sun","year":"2024","unstructured":"Sun H, Zhu Y, Li J, Zhao L, Yang G, Yan Z, et al. PICALM::MLLT10 may indicate a new subgroup of acute leukemias with miscellaneous immunophenotype and poor initial treatment response but showing sensitivity to venetoclax. EJHaem. 2024;5:565\u201372.","journal-title":"EJHaem"},{"key":"2591_CR7","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bjh.19067","volume":"204","author":"C Mark","year":"2024","unstructured":"Mark C, Meshinchi S, Joyce B, Gibson B, Harrison C, Bergmann AK, et al. Treatment outcomes of childhood PICALM::MLLT10 acute leukaemias. Br J Haematol. 2024;204:576\u201384.","journal-title":"Br J Haematol"},{"key":"2591_CR8","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","volume":"36","author":"F Seyfried","year":"2022","unstructured":"Seyfried F, Stirnwei\u00df FU, Niedermayer A, Enzenm\u00fcller S, H\u00f6rl RL, M\u00fcnch V, et al. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL. Leukemia. 2022;36:901\u201312.","journal-title":"Leukemia"},{"key":"2591_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","volume":"4","author":"N Liebers","year":"2023","unstructured":"Liebers N, Bruch PM, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, et al. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial. Nat Cancer. 2023;4:1648\u201359.","journal-title":"Nat Cancer"},{"key":"2591_CR10","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1182\/blood.2024024968","volume":"145","author":"S Kyt\u00f6l\u00e4","year":"2025","unstructured":"Kyt\u00f6l\u00e4 S, V\u00e4nttinen I, Ruokoranta T, Partanen A, Holopainen A, Saad J, et al. Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial. Blood. 2025;145:409\u201321.","journal-title":"Blood"},{"key":"2591_CR11","doi-asserted-by":"crossref","unstructured":"Rigo A, Vaisitti T, Laudanna C, Terrabuio E, Micillo M, Frusteri C, et al. Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter\u2019s syndrome. Cell Death Dis. 2024;15:1\u201315.","DOI":"10.1038\/s41419-024-06707-5"},{"key":"2591_CR12","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1158\/2159-8290.CD-22-0939","volume":"13","author":"A Waclawiczek","year":"2023","unstructured":"Waclawiczek A, Lepp\u00e4 AM, Renders S, Stumpf K, Reyneri C, Betz B, et al. Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine\/Venetoclax. Cancer Discov. 2023;13:1408\u201327.","journal-title":"Cancer Discov"},{"key":"2591_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","volume":"9","author":"MR Luskin","year":"2025","unstructured":"Luskin MR, Shimony S, Keating J, Winer ES, Garcia JS, Stone RM, et al. Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia. Blood Adv. 2025;9:617\u201326.","journal-title":"Blood Adv"},{"key":"2591_CR14","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/cncr.33531","volume":"127","author":"KJ Caldwell","year":"2021","unstructured":"Caldwell KJ, Budhraja A, Opferman JT, Pui CH, Klco JM, Rubnitz JE. Activity of venetoclax against relapsed acute undifferentiated leukemia. Cancer. 2021;127:2608\u201311.","journal-title":"Cancer"},{"key":"2591_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1182\/blood.V94.4.1209","volume":"94","author":"M D\u00f6rdelmann","year":"1999","unstructured":"D\u00f6rdelmann M, Reiter A, Borkhardt A, Ludwig WD, G\u00f6tz N, Viehmann S, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood. 1999;94:1209\u201317.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02591-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02591-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02591-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:04:36Z","timestamp":1748948676000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02591-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2591"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02591-w","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AN, JS, AKB, MZ, RK, FS, DS, CR, LHM, and KMD have nothing to disclose. MB receives research support and consultancy fees from Amgen; is part of the speakers\u2019 bureaus for Amgen, Becton Dickinson, Janssen, and Pfizer; receives travel support from Janssen; and is a member of the advisory boards for Amgen and Incyte. GC receives research grants from Amgen, Clinigen, Jazz, Servier; and consulting fees from Amgen; is on the advisory boards of Amgen and Jazz; and receives travel grants \/ honoria from Amgen, Clinigen, Jazz.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research involving human material has been carried out in accordance with all relevant guidelines and the Declaration of Helsinki. Samples of patients in Ulm had been collected after written informed consent in accordance with the institution\u2019s ethical review board (Ethics Commission, Ulm University, #461\/19). Samples of the patients enrolled in the AIEOP-BFM ALL 2000, 2009 and 2017 studies were collected after written informed consent was obtained from parents or legal guardians. The AIEOP-BFM ALL studies were approved by the ethical committees of all participating institutions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}